146 related articles for article (PubMed ID: 20634674)
1. Treatment of multidrug resistant advanced alveolar soft part sarcoma with sunitinib.
Ghose A; Tariq Z; Veltri S
Am J Ther; 2012 Jan; 19(1):e56-8. PubMed ID: 20634674
[TBL] [Abstract][Full Text] [Related]
2. A retrospective analysis of 14 consecutive Chinese patients with unresectable or metastatic alveolar soft part sarcoma treated with sunitinib.
Li T; Wang L; Wang H; Zhang S; Atikan Kawuli ; Zhang X; Luo Z; Wang C
Invest New Drugs; 2016 Dec; 34(6):701-706. PubMed ID: 27604635
[TBL] [Abstract][Full Text] [Related]
3. Alveolar soft part sarcoma in childhood: is Sunitinib-Sutent® treatment an effective approach?
Hilbert M; Mary P; Larroquet M; Serinet MO; Helfre S; Brisse H; Coulomb A; Orbach D
Pediatr Blood Cancer; 2012 Mar; 58(3):475-6. PubMed ID: 22234817
[No Abstract] [Full Text] [Related]
4. Necrosis of a skin autograft after short-term treatment with sunitinib in a 14-year-old girl with metastatic alveolar soft part sarcoma of the thigh.
Hanzer M; Nebl A; Spendel S; Pilhatsch A; Urban C; Benesch M
Klin Padiatr; 2010 May; 222(3):184-6. PubMed ID: 20514624
[TBL] [Abstract][Full Text] [Related]
5. Long-term results of therapy with sunitinib in metastatic alveolar soft part sarcoma.
Jagodzińska-Mucha P; Świtaj T; Kozak K; Koseła-Paterczyk H; Klimczak A; Ługowska I; Rogala P; Wągrodzki M; Falkowski S; Rutkowski P
Tumori; 2017 May; 103(3):231-235. PubMed ID: 28291905
[TBL] [Abstract][Full Text] [Related]
6. Durable clinical activity of single-agent bevacizumab in a nonagenarian patient with metastatic alveolar soft part sarcoma.
Mir O; Boudou-Rouquette P; Larousserie F; Blanchet B; Babinet A; Anract P; Goldwasser F
Anticancer Drugs; 2012 Aug; 23(7):745-8. PubMed ID: 22331039
[TBL] [Abstract][Full Text] [Related]
7. Sunitinib: from rational design to clinical efficacy.
Chow LQ; Eckhardt SG
J Clin Oncol; 2007 Mar; 25(7):884-96. PubMed ID: 17327610
[TBL] [Abstract][Full Text] [Related]
8. Effective treatment of advanced alveolar soft part sarcoma with sunitinib: A case report.
Ye C; Wang J; Li W; Yuan M; Chai Y
Medicine (Baltimore); 2018 Dec; 97(51):e13584. PubMed ID: 30572461
[TBL] [Abstract][Full Text] [Related]
9. Benefits from pharmacological and pharmacokinetic properties of sunitinib for clinical development.
Sablin MP; Dreyer C; Colichi C; Bouattour M; Delbaldo C; Faivre S; Raymond E
Expert Opin Drug Metab Toxicol; 2010 Aug; 6(8):1005-15. PubMed ID: 20636223
[TBL] [Abstract][Full Text] [Related]
10. Sunitinib in advanced alveolar soft part sarcoma: evidence of a direct antitumor effect.
Stacchiotti S; Negri T; Zaffaroni N; Palassini E; Morosi C; Brich S; Conca E; Bozzi F; Cassinelli G; Gronchi A; Casali PG; Pilotti S
Ann Oncol; 2011 Jul; 22(7):1682-1690. PubMed ID: 21242589
[TBL] [Abstract][Full Text] [Related]
11. Antitumor efficacy of the heparanase inhibitor SST0001 alone and in combination with antiangiogenic agents in the treatment of human pediatric sarcoma models.
Cassinelli G; Lanzi C; Tortoreto M; Cominetti D; Petrangolini G; Favini E; Zaffaroni N; Pisano C; Penco S; Vlodavsky I; Zunino F
Biochem Pharmacol; 2013 May; 85(10):1424-32. PubMed ID: 23466421
[TBL] [Abstract][Full Text] [Related]
12. Pharmacologic application of sunitinib malate in the management of gastrointestinal stromal tumors.
MacIntyre J
Clin J Oncol Nurs; 2007 Apr; 11(2):237-41. PubMed ID: 17573273
[TBL] [Abstract][Full Text] [Related]
13. Response to sunitinib malate in advanced alveolar soft part sarcoma.
Stacchiotti S; Tamborini E; Marrari A; Brich S; Rota SA; Orsenigo M; Crippa F; Morosi C; Gronchi A; Pierotti MA; Casali PG; Pilotti S
Clin Cancer Res; 2009 Feb; 15(3):1096-104. PubMed ID: 19188185
[TBL] [Abstract][Full Text] [Related]
14. Understanding the molecular-based mechanism of action of the tyrosine kinase inhibitor: sunitinib.
Mena AC; Pulido EG; Guillén-Ponce C
Anticancer Drugs; 2010 Jan; 21 Suppl 1():S3-11. PubMed ID: 20110785
[TBL] [Abstract][Full Text] [Related]
15. Activity of sunitinib in extraskeletal myxoid chondrosarcoma.
Stacchiotti S; Pantaleo MA; Astolfi A; Dagrada GP; Negri T; Dei Tos AP; Indio V; Morosi C; Gronchi A; Colombo C; Conca E; Toffolatti L; Tazzari M; Crippa F; Maestro R; Pilotti S; Casali PG
Eur J Cancer; 2014 Jun; 50(9):1657-64. PubMed ID: 24703573
[TBL] [Abstract][Full Text] [Related]
16. Sunitinib.
Rini BI
Expert Opin Pharmacother; 2007 Oct; 8(14):2359-69. PubMed ID: 17927489
[TBL] [Abstract][Full Text] [Related]
17. The use of sunitinib in renal cell carcinoma: where are we now?
Czarnecka AM; Szczylik C; Rini B
Expert Rev Anticancer Ther; 2014 Sep; 14(9):983-99. PubMed ID: 25066545
[TBL] [Abstract][Full Text] [Related]
18. Sunitinib.
Heng DY; Kollmannsberger C
Recent Results Cancer Res; 2010; 184():71-82. PubMed ID: 20072832
[TBL] [Abstract][Full Text] [Related]
19. Sorafenib and sunitinib in the treatment of advanced non-small cell lung cancer.
Gridelli C; Maione P; Del Gaizo F; Colantuoni G; Guerriero C; Ferrara C; Nicolella D; Comunale D; De Vita A; Rossi A
Oncologist; 2007 Feb; 12(2):191-200. PubMed ID: 17296815
[TBL] [Abstract][Full Text] [Related]
20. Sunitinib treatment for patients with advanced clear-cell renal-cell carcinoma after progression on sorafenib.
Zimmermann K; Schmittel A; Steiner U; Asemissen AM; Knoedler M; Thiel E; Miller K; Keilholz U
Oncology; 2009; 76(5):350-4. PubMed ID: 19321976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
